The importance of the disease process and disease‐modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis
Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Nigel Arden(Nuffield Orthopaedic Centre), Tjeerd van Staa(Manchester Academic Health Science Centre), Max Field(University of Glasgow), David J. Fisher(MRC Clinical Trials Unit at UCL), Cyrus Cooper(University Hospital Southampton NHS Foundation Trust)
Cited by 91
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k